Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…Abstract Number: 2472 • 2017 ACR/ARHP Annual Meeting
Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, is in development for rheumatoid arthritis (RA) in…Abstract Number: 2473 • 2017 ACR/ARHP Annual Meeting
Sirukumab Subcutaneous Dose Regimens Maintain Clinical Response over Dosing Intervals in Rheumatoid Arthritis Patients: Results from a Phase 3 Study
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in rheumatoid arthritis (RA)…Abstract Number: 988 • 2016 ACR/ARHP Annual Meeting
Risk of Rheumatoid Arthritis after Transfusion of Blood from Donors Later Diagnosed with Rheumatoid Arthritis: A Retrospective Cohort Study
Background/Purpose: Rheumatoid Arthritis (RA) is a disease that can have a long sub-clinical phase. During this phase the person with pre-RA could have factors in…Abstract Number: 1914 • 2016 ACR/ARHP Annual Meeting
Immune Recognition of a Novel Citrullinated Epitope of Cartilage Proteoglycan Aggrecan in Mice with Proteoglycan-Induced Arthritis and in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease leading to the inflammatory destruction of synovial joints. Anti-citrullinated protein antibodies (ACPA) are frequently detected in the…Abstract Number: 2650 • 2016 ACR/ARHP Annual Meeting
Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
Background/Purpose: In the SIRROUND-D study, sirukumab, a human anti–IL-6 cytokine monoclonal antibody, significantly reduced radiographic progression after 52 wks of treatment vs placebo in patients…Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…Abstract Number: 3217 • 2016 ACR/ARHP Annual Meeting
Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Background/Purpose: The establishment of longitudinal pre-clinical RA cohorts is beginning to provide important insights into the mechanisms that precede the onset of clinically detectable disease.…Abstract Number: 469 • 2016 ACR/ARHP Annual Meeting
Role of Microbiota in Development of Autoimmune Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease with an unknown cause. Observations of dysbiosis and mucosal inflammation in patients with RA has raised interest…Abstract Number: 470 • 2016 ACR/ARHP Annual Meeting
Crucial Involvement of Citrullinated Proteins and ACPA in the Development of Peptide-Glucose-6-Phosphate Isomerase Induced Arthritis
Background/Purpose: Various citrullinated proteins and anti-citrullinated protein antibodies (ACPA) are increased in patients with rheumatoid arthritis (RA). ACPA have high specificity for RA, and are…Abstract Number: 635 • 2016 ACR/ARHP Annual Meeting
Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study
Background/Purpose: To investigate the variables associated to lack of adherence to subcutaneous (SC) biological drug in patients with rheumatoid arthritis (RA) after 1 year of…Abstract Number: 510 • 2015 ACR/ARHP Annual Meeting
Histologic Scoring of Arthroplasty Synovial Samples May Predict RA Flare
Background/Purpose: Patients with established RA undergoing total joint arthroplasty (TJA) frequently experience a disease flare within 6 weeks of surgery. This study aims to determine…Abstract Number: 1318 • 2015 ACR/ARHP Annual Meeting
Prediction of Large Joint Destruction in Patients with Rheumatoid Arthritis Using FDG-PET/CT: A Prospective Study
Background/Purpose: The assessments of joint damage in patients with rheumatoid arthritis (RA) are mainly restricted to small joints in the hands and feet. However, the…Abstract Number: 1647 • 2015 ACR/ARHP Annual Meeting
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Rheumatoid Arthritis
Background/Purpose: Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, provides symptom modification in RA patients. Previous dose-ranging studies in RA demonstrated the clinical efficacy of etoricoxib 90…Abstract Number: 2138 • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Background/Purpose: Duvelisib is a potent, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ,γ being developed for hematologic malignancies, and was also explored in early phase studies in…
ACR Meeting Abstracts